Stoke Therapeutics (STOK) Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" STOK shares.
View STOK analyst ratings or view top-rated stocks.

9 brokerages have issued 1-year price objectives for Stoke Therapeutics' stock. Their STOK share price forecasts range from $12.00 to $35.00. On average, they expect the company's stock price to reach $23.50 in the next year. This suggests a possible upside of 462.2% from the stock's current price.
View analysts price targets for STOK or view top-rated stocks among Wall Street analysts.

Stoke Therapeutics' stock was trading at $9.23 at the beginning of 2023. Since then, STOK stock has decreased by 54.7% and is now trading at $4.18.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our STOK earnings forecast.

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings data on Monday, August, 7th. The company reported ($0.69) EPS for the quarter, missing analysts' consensus estimates of ($0.63) by $0.06. The company earned ($2.48) million during the quarter, compared to analysts' expectations of $4 million. Stoke Therapeutics had a negative net margin of 679.83% and a negative trailing twelve-month return on equity of 52.94%.

ETFs with the largest weight of Stoke Therapeutics (NASDAQ:STOK) stock in their portfolio include Morningstar US Small Growth (MSGR) and Simplify Propel Opportunities ETF (SURI).Global X Genomics & Biotechnology ETF (GNOM).

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology (MRVL) and Invitae (NVTA).

(STOK) raised $100 million in an initial public offering on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

Stoke Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Cowen AND Company LLC (8.42%), BlackRock Inc. (5.18%), Geode Capital Management LLC (1.36%), State Street Corp (1.25%), Granahan Investment Management LLC (1.20%) and M28 Capital Management LP (0.78%). Insiders that own company stock include Apple Tree Partners Iv, LP, Arthur Tzianabos, Barry Ticho, Edward M Md Kaye, Gene Liau, Huw M Nash, Huw M Nash, Jonathan Allan and Stephen J Tulipano.
View institutional ownership trends.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STOK stock can currently be purchased for approximately $4.18.

Stoke Therapeutics (NASDAQ:STOK) has a market capitalization of $185.01 million and generates $12.40 million in revenue each year. The company earns $-101,070,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

The company employs 117 workers across the globe.

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The official website for the company is www.stoketherapeutics.com. The company can be reached via phone at (781) 430-8200 or via email at ir@stoketherapeutics.com.